Results 161 to 170 of about 5,988 (201)
Some of the next articles are maybe not open access.
Phlebologie, 2015
SummaryPatients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary.
openaire +1 more source
SummaryPatients with cancer are at increased risk of venous thromboembolism (VTE). At the same time they have often an underlying bleeding risk. That can often make decisions surrounding the administration of anticoagulants complicate. Individual risk-benefit calculation is necessary.
openaire +1 more source
DOAC’s in de huisartsenpraktijk
Praktische Huisartsgeneeskunde, 2017Het NHG heeft recent een nieuw standpunt anticoagulantia gepubliceerd waarin geen voorkeur meer is voor de cumarinederivaten. DOAC’s worden sindsdien ook vergoed op recept van de huisarts, wat een aantal verwijzingen naar de specialist overbodig zal maken. Wat zijn voor- en nadelen en (contra)indicaties?
openaire +1 more source
To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?
JAMA Cardiology, 2021Arun, Manmadhan +2 more
openaire +2 more sources
DOAC dose adjustment in renal impairment
Drug and Therapeutics Bulletin, 2020Abstract Review of: Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart 2020;106:358–364.
openaire +2 more sources
To DOAC or Not to DOAC for Left Ventricular Thrombi—What Is the Dose?—Reply
JAMA Cardiology, 2021Austin A, Robinson +2 more
openaire +2 more sources
Nederlands tijdschrift voor geneeskunde, 2020
Direct oral anticoagulants (DOACs) are increasingly being prescribed for stroke prevention in patients with atrial fibrillation or for treating venous thromboembolism. In this short overview, we provide some guidance on possible differences between available DOACs as well as a comparison with traditional treatments using vitamin K antagonists.
Sander, van Doorn +2 more
openaire +1 more source
Direct oral anticoagulants (DOACs) are increasingly being prescribed for stroke prevention in patients with atrial fibrillation or for treating venous thromboembolism. In this short overview, we provide some guidance on possible differences between available DOACs as well as a comparison with traditional treatments using vitamin K antagonists.
Sander, van Doorn +2 more
openaire +1 more source
Filtering Out Use of DOACs in Hemodialysis
Annals of Pharmacotherapy, 2017Published data exploring the best approach to initiating and maintaining anticoagulation in the setting of renal support therapy are scarce, as these patients were excluded in clinical trials. When developing an anticoagulation regimen in this setting, it is important to assess thrombosis risk, identify the unique drivers for thrombosis and bleeding ...
William E, Dager, Jin A, Lee
openaire +2 more sources
An update on the bleeding risks associated with DOACs
Drug and Therapeutics Bulletin, 2017The direct oral anticoagulants (DOACs), also referred to as novel (or non-vitamin K antagonist) oral anticoagulants (NOACs), represent a major development in anticoagulation therapy due to their rapid onset of action, predictable dose–response with fixed doses and limited interactions with food and drugs.1,2 However, these agents have been in ...
openaire +2 more sources
[New direct oral oral anticoagulants (DOACs) - indications of DOACs].
Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2014The direct oral anticoagulants (DOACs) were developed because of the urgent therapeutic need due to the deficits of vitamin K antagonist therapy. The predominant indications in internal medicine are the acute treatment and secondary prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) as well as stroke prevention in patients with ...
openaire +1 more source
Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays
Thrombosis Research, 2020Tinne Monteyne +2 more
openaire +2 more sources